X

Trial Profile

Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Galunisertib (Primary) ; Lomustine
Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
Focus Adverse reactions; First in man
Sponsors Eli Lilly and Company

Most Recent Events

10 Jun 2023 Planned End Date changed from 31 Dec 2023 to 30 Sep 2024.
13 Feb 2023 Planned End Date changed from 6 Dec 2023 to 31 Dec 2023.
18 Oct 2022 Planned End Date changed from 6 Dec 2022 to 6 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com